[go: up one dir, main page]

EP4061808A4 - COMPOSITIONS AND METHODS FOR TREATING DISORDERS ALLEVIATED BY ACTIVATION OF THE MUSCARINIC RECEPTOR - Google Patents

COMPOSITIONS AND METHODS FOR TREATING DISORDERS ALLEVIATED BY ACTIVATION OF THE MUSCARINIC RECEPTOR Download PDF

Info

Publication number
EP4061808A4
EP4061808A4 EP20888871.9A EP20888871A EP4061808A4 EP 4061808 A4 EP4061808 A4 EP 4061808A4 EP 20888871 A EP20888871 A EP 20888871A EP 4061808 A4 EP4061808 A4 EP 4061808A4
Authority
EP
European Patent Office
Prior art keywords
activation
compositions
methods
muscarinic receptor
treating disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20888871.9A
Other languages
German (de)
French (fr)
Other versions
EP4061808A1 (en
Inventor
Stephen Brannan
Andrew Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karuna Therapeutics Inc
Original Assignee
Karuna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karuna Therapeutics Inc filed Critical Karuna Therapeutics Inc
Publication of EP4061808A1 publication Critical patent/EP4061808A1/en
Publication of EP4061808A4 publication Critical patent/EP4061808A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP20888871.9A 2019-11-18 2020-11-17 COMPOSITIONS AND METHODS FOR TREATING DISORDERS ALLEVIATED BY ACTIVATION OF THE MUSCARINIC RECEPTOR Pending EP4061808A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962936837P 2019-11-18 2019-11-18
US202063030780P 2020-05-27 2020-05-27
PCT/US2020/060859 WO2021101875A1 (en) 2019-11-18 2020-11-17 Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Publications (2)

Publication Number Publication Date
EP4061808A1 EP4061808A1 (en) 2022-09-28
EP4061808A4 true EP4061808A4 (en) 2023-12-20

Family

ID=75980892

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20888871.9A Pending EP4061808A4 (en) 2019-11-18 2020-11-17 COMPOSITIONS AND METHODS FOR TREATING DISORDERS ALLEVIATED BY ACTIVATION OF THE MUSCARINIC RECEPTOR

Country Status (5)

Country Link
EP (1) EP4061808A4 (en)
JP (1) JP2023503056A (en)
CN (4) CN115667235B (en)
CA (1) CA3161952A1 (en)
WO (1) WO2021101875A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005802B1 (en) 2018-09-28 2022-02-15 Karuna Therapeutics, Inc ORAL PHARMACEUTICAL COMPOSITION
IL305412A (en) * 2021-02-24 2023-10-01 Karuna Therapeutics Inc Methods for the treatment of disorders are improved by activating muscarinic receptors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170095465A1 (en) * 2009-07-22 2017-04-06 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
HUE044653T2 (en) * 2009-07-22 2019-11-28 PureTech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP2523944A4 (en) * 2010-01-11 2013-06-19 Mithridion Inc Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
BR112021005802B1 (en) * 2018-09-28 2022-02-15 Karuna Therapeutics, Inc ORAL PHARMACEUTICAL COMPOSITION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170095465A1 (en) * 2009-07-22 2017-04-06 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"ACNP 57Annual Meeting: Poster Session I", NEUROPSYCHOPHARMACOLOGY, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 43, no. Suppl 1, 1 December 2018 (2018-12-01), pages 77 - 227, XP037114788, ISSN: 0893-133X, [retrieved on 20181206], DOI: 10.1038/S41386-018-0266-7 *

Also Published As

Publication number Publication date
EP4061808A1 (en) 2022-09-28
WO2021101875A1 (en) 2021-05-27
CN115667235A (en) 2023-01-31
CA3161952A1 (en) 2021-05-27
CN120478350A (en) 2025-08-15
JP2023503056A (en) 2023-01-26
CN115667235B (en) 2025-06-17
CN120514706A (en) 2025-08-22
CN120459098A (en) 2025-08-12

Similar Documents

Publication Publication Date Title
IL269378A (en) Optimized antibody compositions for treatment of ocular disorders
EP3448398A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP3445451A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LYSOSOMAL DISORDERS AND DISORDERS CHARACTERIZED BY LYSOSOMAL DYSFUNCTION
EP3500267A4 (en) NICOTINAMIDE RIBOSIDE AND PTEROSTILBENE COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
EP3704108A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BLOOD DISORDERS
EP3368088C0 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PEROXISOMAL DISORDERS AND LEUCODYSTROPHIES
MA44875A (en) COMPOSITIONS FOR THE TREATMENT OF ACID BASIC DISORDERS
EP3774743C0 (en) PRODRUG COMPOUNDS ACTIVATED BY AKR1C3 AND THEIR USE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
IL281809A (en) Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors
EP3352749A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
MA50391A (en) NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
MA47212A (en) TREATMENT METHODS FOR NEUROLOGICAL DISORDERS
MA51672A (en) COMPOUNDS INTENDED FOR THE TREATMENT OF KINASIS-DEPENDENT DISORDERS
EP3621434A4 (en) TREATMENT METHODS FOR NEUROPSYCHIATRIC DISORDERS
MA51056A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
EP3902536A4 (en) COMPOSITIONS AND METHODS OF TREATING NEURODEGENERATIVE DISORDERS
MA54150A (en) COMPOSITIONS AND METHODS OF TREATING ESTROGEN DEPENDENT DISORDERS
EP3352755A4 (en) NOVEL COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP3826650A4 (en) METHODS OF TREATING NEUROLOGICAL DISORDERS
MA52778A (en) METHODS OF TREATMENT OF DISORDERS ASSOCIATED WITH THE S1P1 RECEPTOR
MA52941A (en) THIOPHENE DERIVATIVES FOR THE TREATMENT OF IGE-CAUSED DISORDERS
EP3442554A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH NEOVASCULARIZATION
EP3334710A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS
MA53741A (en) METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS
EP4061808A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISORDERS ALLEVIATED BY ACTIVATION OF THE MUSCARINIC RECEPTOR

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080197

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0401040000

Ipc: A61K0009160000

A4 Supplementary search report drawn up and despatched

Effective date: 20231121

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20231115BHEP

Ipc: A61P 25/18 20060101ALI20231115BHEP

Ipc: A61K 31/46 20060101ALI20231115BHEP

Ipc: A61K 31/4439 20060101ALI20231115BHEP

Ipc: C07D 405/14 20060101ALI20231115BHEP

Ipc: C07D 401/14 20060101ALI20231115BHEP

Ipc: C07D 401/04 20060101ALI20231115BHEP

Ipc: A61K 9/16 20060101AFI20231115BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250721